CTCX
Income statement / Annual
Last year (2023), Carmell Therapeutics Corporation's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Carmell Therapeutics Corporation's net income was -$15.45 M.
See Carmell Therapeutics Corporation,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$124,788.00
|
$242,556.00
|
$0.00
|
| Gross Profit |
-$124,788.00
|
-$242,556.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
| Research and Development Expenses |
$2.50 M
|
$2.20 M
|
$982,837.00
|
| General & Administrative Expenses |
$0.00
|
$3.22 M
|
$863,333.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$2.60 M
|
$3.22 M
|
$863,333.00
|
| Other Expenses |
$0.00
|
$10,922.00
|
$37,378.00
|
| Operating Expenses |
$5.09 M
|
$5.51 M
|
$1.94 M
|
| Cost And Expenses |
$5.22 M
|
$5.51 M
|
$1.94 M
|
| Interest Income |
$0.00
|
$2.25 M
|
$8,091.00
|
| Interest Expense |
$889,318.00
|
$3.75 M
|
$2.50 M
|
| Depreciation & Amortization |
$124,788.00
|
$242,556.00
|
$242,124.00
|
| EBITDA |
-$15.19 M |
-$5.25 M |
-$1.66 M |
| EBITDA Ratio |
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$10.99 M
|
-$3.54 M
|
-$4.54 M
|
| Income Before Tax |
-$16.21 M
|
-$9.05 M
|
-$6.48 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
| Income Tax Expense |
-$760,163.00
|
$391,198.00
|
$2.54 M
|
| Net Income |
-$15.45 M
|
-$9.05 M
|
-$6.48 M
|
| Net Income Ratio |
0
|
0
|
0
|
| EPS |
-1.46 |
-0.46 |
-0.33 |
| EPS Diluted |
-1.46 |
-0.46 |
-0.33 |
| Weighted Average Shares Out |
$11.02 M
|
$19.77 M
|
$19.77 M
|
| Weighted Average Shares Out Diluted |
$11.02 M
|
$19.77 M
|
$19.77 M
|
| Link |
|
|
|
